Lydia Wai Ting Cheung

List of Publications by Year
in descending order

26	2,186	471371 17	526166 27
papers	citations	h-index	g-index

27	27	27	4614
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell, 2015, 28, 515-528.	7.7	426
2	High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discovery, 2011, 1, 170-185.	7.7	419
3	Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell, 2018, 33, 450-462.e10.	7.7	213
4	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Research, 2012, 22, 2120-2129.	2.4	206
5	Estrogen Regulates Snail and Slug in the Down-Regulation of E-Cadherin and Induces Metastatic Potential of Ovarian Cancer Cells through Estrogen Receptor Î±. Molecular Endocrinology, 2008, 22, 2085-2098.	3.7	169
6	Gonadotropinâ€releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS Journal, 2008, 275, 5479-5495.	2.2	115
7	Gonadotropin-Releasing Hormone Promotes Ovarian Cancer Cell Invasiveness through c-Jun NH2-Terminal Kinaseâ€“Mediated Activation of Matrix Metalloproteinase (MMP)-2 and MMP-9. Cancer Research, 2006, 66, 10902-10910.	0.4	92
8	Pigment Epithelium-Derived Factor Is Estrogen Sensitive and Inhibits the Growth of Human Ovarian Cancer and Ovarian Surface Epithelial Cells. Endocrinology, 2006, 147, 4179-4191.	1.4	87
9	Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors. Cancer Cell, 2014, 26, 479-494.	7.7	73
10	Regulation of the PI3K pathway through a p85Î± monomerâ€“homodimer equilibrium. ELife, 2015, 4, e06866.	2.8	65
11	Ginsenoside-Rg1 induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fibroblast growth factor receptor-1. Cardiovascular Research, 2011, 89, 419-425.	1.8	51
12	Somatic Mutations of PIK3R1 Promote Gliomagenesis. PLoS ONE, 2012, 7, e49466.	1.1	49
13	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. Nature Communications, 2019, 10, 716.	5.8	36
14	Exposure to light at night (LAN) and risk of breast cancer: A systematic review and meta-analysis. Science of the Total Environment, 2021, 762, 143159.	3.9	32
15	A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets. Cell Reports, 2020, 32, 108020.	2.9	27
16	p85Î² regulates autophagic degradation of AXL to activate oncogenic signaling. Nature Communications, 2020, 11, 2291.	5.8	23
17	Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine, 2007, 31, 311-320.	2.2	20
18	Targeting Gonadotropin-releasing Hormone Receptor Inhibits the Early Step of Ovarian Cancer Metastasis by Modulating Tumor-mesothelial Adhesion. Molecular Therapy, 2013, 21, 78-90.	3.7	20

#	Article	IF	Citations
19	Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 262.	3.5	13
20	A pathway map of AXL receptor-mediated signaling network. Journal of Cell Communication and Signaling, 2021, 15, 143-148.	1.8	13
21	Cancerâ€associated missense mutations enhance the pluripotency reprogramming activity of OCT4 and SOX17. FEBS Journal, 2020, 287, 122-144.	2.2	11
22	Cancer-associated mutations in the p85Î± N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
23	CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes. FEBS Letters, 2007, 581, 4668-4674.	1.3	7
24	p85Î² alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair. Neoplasia, 2021, 23, 718-730.	2.3	6
25	Strategic Combination Therapies for Ovarian Cancer. Current Cancer Drug Targets, 2020, 20, 573-585.	0.8	2
26	Oncogenic pathway driven by p85Î²: upstream signals to activate p110. Molecular and Cellular Oncology, 2020, 7, 1780900.	0.3	1